Darunavir / Cobicistat / Emtricitabin / Tenofoviralafenamid (2) – Symtuza®
HIV infection, aged ≥ 6 years to < 12 years
Characteristics
| Start date | 01.10.2026 |
|---|---|
| Resolution | 01.04.2027 – active procedure |
| INN | Darunavir/Cobicistat/Emtricitabin/Tenofoviralafenamid |
| Brand name | Symtuza® |
| Pharm. company | Johnson & Johnson |
| G-BA Procedure ID | D-1389 |
| Therapeutic area | Infectious diseases |
| Reason for procedure | New therapeutic indication |
Associated procedures
| Darunavir / Cobicistat / Emtricitabin / Tenofoviralafenamid (2) | Symtuza® | Johnson & Johnson | HIV infection, aged ≥ 6 years to < 12 years | n.d. | active procedure | |
| Darunavir / Cobicistat / Emtricitabin / Tenofoviralafenamid (1) | Symtuza® | Janssen-Cilag GmbH | HIV infection | 62,050 | 100% additional benefit not proven |
<< List of all resolutions